Literature DB >> 24295432

Vascular alterations in the sprague-dawley rat mandible during intravenous bisphosphonate therapy.

Chestine S Guevarra1, James L Borke, Mark R Stevens, Fredrick C Bisch, Ibrahim Zakhary, Regina Messer, Robert C Gerlach, Mohammed E Elsalanty.   

Abstract

Long-term use of intravenous bisphosphonates, such as zoledronic acid (zoledronate), has been linked to bisphosphonate-related osteonecrosis of the jaw (BRONJ). Invasive dental surgery seems to trigger the bone necrosis in most cases. To determine the effects of zoledronic acid on the vascular structure of the rat mandible. Extracted of the mandibular first molar in rats that received 2 IV injections of zoledronate (20 μg/kg), 4 weeks apart. Zoledronate-treated rats (n = 18) were then compared to a control group of untreated rats (n = 18). At the fourth, eighth, and 12th week after molar extraction, 8 rat mandibles from each group were perfused with 35% radiopaque triphenylbismuth in methyl methacrylate via carotid artery perfusion. Mandibles were harvested and examined by micro-CT to assess the spatial and dimensional changes of the vasculature as a result of zoledronate treatment. The micro-CT analysis showed that zoledronic acid-treated rats had blood vessels that were thicker, less connected, and less ordered than control rats that were not exposed to zoledronic acid. This study demonstrated that treatment with zoledronic acid in rats is associated with vascular changes in alveolar bone. Further studies are underway to explore whether these vascular changes contribute to the pathogenesis of BRONJ.

Entities:  

Keywords:  BRONJ; bisphosphonate; mandible; rat model; vascular parameters

Mesh:

Substances:

Year:  2013        PMID: 24295432     DOI: 10.1563/AAID-JOI-D-13-00074

Source DB:  PubMed          Journal:  J Oral Implantol        ISSN: 0160-6972            Impact factor:   1.779


  7 in total

1.  Periosteal microcirculatory reactions in a zoledronate-induced osteonecrosis model of the jaw in rats.

Authors:  Ágnes Janovszky; Andrea Szabó; Renáta Varga; Dénes Garab; Mihály Boros; Csilla Mester; Nikolett Beretka; Tamás Zombori; Hans-Peter Wiesmann; Ricardo Bernhardt; Imre Ocsovszki; Péter Balázs; József Piffkó
Journal:  Clin Oral Investig       Date:  2014-10-30       Impact factor: 3.573

Review 2.  Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis.

Authors:  Akanksha Srivastava; Graciela M Nogueras Gonzalez; Yimin Geng; Alexander M Won; Jeffrey Myers; Yisheng Li; Mark S Chambers
Journal:  J Immunother Precis Oncol       Date:  2021-09-30

3.  Antiresorptive drug-related changes of the mandibular bone densitiy in medication-related osteonecrosis of the jaw patients.

Authors:  Nils Heim; Werner Götz; Franz-Josef Kramer; Anton Faron
Journal:  Dentomaxillofac Radiol       Date:  2019-09-17       Impact factor: 2.419

Review 4.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

5.  A Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major Trauma.

Authors:  R Nicole Howie; James L Borke; Zoya Kurago; Asma Daoudi; James Cray; Ibrahim E Zakhary; Tara L Brown; J Nathan Raley; Loan T Tran; Regina Messer; Fardous Medani; Mohammed E Elsalanty
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

6.  Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB.

Authors:  Si-Yong Gao; Guang-Sen Zheng; Lin Wang; Yu-Jie Liang; Si-En Zhang; Xiao-Mei Lao; Kan Li; Gui-Qing Liao
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

Review 7.  Angiogenesis in the Development of Medication-Related Osteonecrosis of the Jaws: An Overview.

Authors:  Andreas Max Pabst; Maximilian Krüger; Sebastian Blatt; Thomas Ziebart; Roman Rahimi-Nedjat; Elisabeth Goetze; Christian Walter
Journal:  Dent J (Basel)       Date:  2016-12-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.